FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301606468> ?p ?o ?g. }

• W4301606468 endingPage "954" @default.
• W4301606468 startingPage "945" @default.
• W4301606468 abstract "Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking. This post hoc, indirect treatment comparison (ITC) used pooled data from the phase 3 EORTC 18,071 (ipilimumab vs. placebo) and CheckMate 238 (nivolumab vs. ipilimumab) trials to assess RFS and OS with nivolumab versus placebo and the numbers needed to treat (NNT) over 4 years.Patients with resected stage IIIB-C cutaneous melanoma (American Joint Committee on Cancer seventh edition) were included. Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics. RFS NNTs were calculated for nivolumab versus ipilimumab and placebo. OS NNTs were calculated for nivolumab versus placebo. To adjust for different post-recurrence treatments, the difference in post-recurrence survival between the two ipilimumab arms was added to OS of the placebo arm.This ITC included 278, 643, and 365 patients treated with nivolumab, ipilimumab, and placebo, respectively. Following IPTW, nivolumab was associated with improved RFS versus placebo (hazard ratio [HR]: 0.49; 95% confidence interval [CI] 0.39-0.61) and ipilimumab (HR: 0.69; 95% CI 0.56-0.85). RFS NNT was 4.2 for nivolumab versus placebo and 8.9 for nivolumab versus ipilimumab. After post-recurrence survival adjustment, weighted 4-year OS rates were 75.8% for nivolumab and 64.1% for placebo; OS NNT for nivolumab versus placebo was 8.5.In patients with resected stage IIIB-C cutaneous melanoma in this ITC, nivolumab improved RFS versus placebo and ipilimumab, and OS versus placebo after post-recurrence survival adjustment." @default.
• W4301606468 created "2022-10-05" @default.
• W4301606468 creator A5001330237 @default.
• W4301606468 creator A5001550948 @default.
• W4301606468 creator A5003642180 @default.
• W4301606468 creator A5037458498 @default.
• W4301606468 creator A5040291209 @default.
• W4301606468 creator A5065311807 @default.
• W4301606468 creator A5082712288 @default.
• W4301606468 creator A5087789076 @default.
• W4301606468 creator A5089520820 @default.
• W4301606468 creator A5091860403 @default.
• W4301606468 date "2022-10-05" @default.
• W4301606468 modified "2023-10-17" @default.
• W4301606468 title "Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival" @default.
• W4301606468 cites W1995945562 @default.
• W4301606468 cites W2017766892 @default.
• W4301606468 cites W2033209427 @default.
• W4301606468 cites W2056108924 @default.
• W4301606468 cites W2070825440 @default.
• W4301606468 cites W2094916253 @default.
• W4301606468 cites W2118863192 @default.
• W4301606468 cites W2128449242 @default.
• W4301606468 cites W2131365547 @default.
• W4301606468 cites W2529373149 @default.
• W4301606468 cites W2607052590 @default.
• W4301606468 cites W2752210999 @default.
• W4301606468 cites W2752227448 @default.
• W4301606468 cites W2765819707 @default.
• W4301606468 cites W2793359570 @default.
• W4301606468 cites W2892714253 @default.
• W4301606468 cites W2943229739 @default.
• W4301606468 cites W2964599082 @default.
• W4301606468 cites W2969679797 @default.
• W4301606468 cites W2981854221 @default.
• W4301606468 cites W2997216818 @default.
• W4301606468 cites W3021516239 @default.
• W4301606468 cites W3023035505 @default.
• W4301606468 cites W3024460671 @default.
• W4301606468 cites W3082456432 @default.
• W4301606468 cites W3087697977 @default.
• W4301606468 cites W3096216569 @default.
• W4301606468 cites W3153228158 @default.
• W4301606468 cites W3201787835 @default.
• W4301606468 cites W3205113203 @default.
• W4301606468 doi "https://doi.org/10.1007/s00262-022-03302-5" @default.
• W4301606468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36197494" @default.
• W4301606468 hasPublicationYear "2022" @default.
• W4301606468 type Work @default.
• W4301606468 citedByCount "0" @default.
• W4301606468 crossrefType "journal-article" @default.
• W4301606468 hasAuthorship W4301606468A5001330237 @default.
• W4301606468 hasAuthorship W4301606468A5001550948 @default.
• W4301606468 hasAuthorship W4301606468A5003642180 @default.
• W4301606468 hasAuthorship W4301606468A5037458498 @default.
• W4301606468 hasAuthorship W4301606468A5040291209 @default.
• W4301606468 hasAuthorship W4301606468A5065311807 @default.
• W4301606468 hasAuthorship W4301606468A5082712288 @default.
• W4301606468 hasAuthorship W4301606468A5087789076 @default.
• W4301606468 hasAuthorship W4301606468A5089520820 @default.
• W4301606468 hasAuthorship W4301606468A5091860403 @default.
• W4301606468 hasBestOaLocation W43016064681 @default.
• W4301606468 hasConcept C121608353 @default.
• W4301606468 hasConcept C126322002 @default.
• W4301606468 hasConcept C142724271 @default.
• W4301606468 hasConcept C143998085 @default.
• W4301606468 hasConcept C17923572 @default.
• W4301606468 hasConcept C204787440 @default.
• W4301606468 hasConcept C207103383 @default.
• W4301606468 hasConcept C27081682 @default.
• W4301606468 hasConcept C2777658100 @default.
• W4301606468 hasConcept C2777701055 @default.
• W4301606468 hasConcept C2777982462 @default.
• W4301606468 hasConcept C2780030458 @default.
• W4301606468 hasConcept C2781433595 @default.
• W4301606468 hasConcept C44249647 @default.
• W4301606468 hasConcept C502942594 @default.
• W4301606468 hasConcept C71924100 @default.
• W4301606468 hasConceptScore W4301606468C121608353 @default.
• W4301606468 hasConceptScore W4301606468C126322002 @default.
• W4301606468 hasConceptScore W4301606468C142724271 @default.
• W4301606468 hasConceptScore W4301606468C143998085 @default.
• W4301606468 hasConceptScore W4301606468C17923572 @default.
• W4301606468 hasConceptScore W4301606468C204787440 @default.
• W4301606468 hasConceptScore W4301606468C207103383 @default.
• W4301606468 hasConceptScore W4301606468C27081682 @default.
• W4301606468 hasConceptScore W4301606468C2777658100 @default.
• W4301606468 hasConceptScore W4301606468C2777701055 @default.
• W4301606468 hasConceptScore W4301606468C2777982462 @default.
• W4301606468 hasConceptScore W4301606468C2780030458 @default.
• W4301606468 hasConceptScore W4301606468C2781433595 @default.
• W4301606468 hasConceptScore W4301606468C44249647 @default.
• W4301606468 hasConceptScore W4301606468C502942594 @default.
• W4301606468 hasConceptScore W4301606468C71924100 @default.
• W4301606468 hasIssue "4" @default.
• W4301606468 hasLocation W43016064681 @default.
• W4301606468 hasLocation W43016064682 @default.
• W4301606468 hasLocation W43016064683 @default.

• next